Dr. Edwin P. Alyea

Cellular Therapy Specialist , Experience: 28

Book Appointment

About Doctor

Dr. Edwin P. Alyea specialises in treating blood cancer patients who are considering stem cell or bone marrow transplants. Over the last 20 years, there have been substantial advancements in transplantation, which has resulted in better outcomes. These advancements include the capacity to utilise lower chemotherapy dosages to lessen toxicity in patients, as well as methods to reduce the likelihood of relapse. I am interested in utilising novel medicines and techniques to improve outcomes following stem cell transplantation for blood malignancies. It is critical to collaborate with patients to define their treatment goals and the best course of action. For many years following their transplant, I have loved working with patients and their families.

Board Certification

American Board of Internal Med, Medical Oncology


Medical Oncology, Dana-Farber Cancer Institute (Massachusetts), 1992-1995


Internal Medicine, Brigham and Women’s Hospital (Massachusetts), 1989-1992


MD, Duke University, 1989


Duke Hospital, Durham, United States


  • Adult Bone Marrow and Stem Cell Transplant
  • Autologous Transplant
  • Allogeneic Transplant
  • Syngeneic Transplant

Procedures Performed

Research & Publications

  • Hourigan, Christopher S., Laura W. Dillon, Gege Gui, Brent R. Logan, Mingwei Fei, Jack Ghannam, Yuesheng Li, et al. “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.” J Clin Oncol 38, no. 12 (April 20, 2020): 1273–83. https://doi.org/10.1200/JCO.19.03011.
  • Soiffer, Robert J., Haesook T. Kim, Joseph McGuirk, Mitchell E. Horwitz, Laura Johnston, Mrinal M. Patnaik, Witold Rybka, et al. “Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.” J Clin Oncol 35, no. 36 (December 20, 2017): 4003–11. https://doi.org/10.1200/JCO.2017.75.8177.
  • Liu, Hien Duong, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani, Taiga Nishihori, Baldeep Wirk, Amer Beitinjaneh, et al. “Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.” Biol Blood Marrow Transplant 23, no. 5 (May 2017): 767–75. https://doi.org/10.1016/j.bbmt.2017.01.078.
  • Scott, Bart L., Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine, David L. Porter, Richard T. Maziarz, et al. “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.” J Clin Oncol 35, no. 11 (April 10, 2017): 1154–61. https://doi.org/10.1200/JCO.2016.70.7091.
  • Shaffer, Brian C., Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valcárcel, Michael R. Grunwald, et al. “Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.” J Clin Oncol 34, no. 16 (June 1, 2016): 1864–71. https://doi.org/10.1200/JCO.2015.65.0515.
  • Devine, Steven M., Kouros Owzar, William Blum, Flora Mulkey, Richard M. Stone, Jack W. Hsu, Richard E. Champlin, et al. “Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.” J Clin Oncol 33, no. 35 (December 10, 2015): 4167–75. https://doi.org/10.1200/JCO.2015.62.7273.
  • Jacobson, Caron A., Lixian Sun, Haesook T. Kim, Sean M. McDonough, Carol G. Reynolds, Michael Schowalter, John Koreth, et al. “Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.” Biol Blood Marrow Transplant 20, no. 5 (May 2014): 668–75. https://doi.org/10.1016/j.bbmt.2014.01.021.
  • Cutler, Corey, Haesook T. Kim, Bhavjot Bindra, Stefanie Sarantopoulos, Vincent T. Ho, Yi-Bin Chen, Jacalyn Rosenblatt, et al. “Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.” Blood 122, no. 8 (August 22, 2013): 1510–17. https://doi.org/10.1182/blood-2013-04-495895.
  • Porcheray, Fabrice, David B. Miklos, Blair H. Floyd, Stefanie Sarantopoulos, Roberto Bellucci, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea, Jerome Ritz, and Emmanuel Zorn. “Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation.” Transplantation 92, no. 3 (August 15, 2011): 359–65. https://doi.org/10.1097/TP.0b013e3182244cc3.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy